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Available online 19 January 2016Background: Chronic kidney disease (CKD) has been shown to be associated with diabetic retinopathy (DR) and
age-relatedmacular degeneration (AMD), leading causes of blindness in elderly adults in previous studies. How-
ever, the association of CKDwith visual impairment (VI) is not clear.We aimed to examine the association of CKD
with VI and other age-related ocular diseases in a population-based sample of Asian adults.
Methods:We analyzed data from 10,033 adults aged 40–80 years who participated in the Singapore Epidemiol-
ogy of Eye Diseases (SEED, 2004–11) Study. CKD was deﬁned as an estimated glomerular ﬁltration rate (eGFR)
b60 ml/min/1.73 m2 from serum creatinine. VI was deﬁned as best-corrected visual acuity b20/40 in the better
eye. Cataract, retinopathy, DR, glaucoma and AMDwere assessed using standardized ocular examination, retinal
photography and visual ﬁeld assessments. The associations of CKDwith VI and ocular conditionswere examined
using logistic regression models adjusted for age, sex, race, smoking, alcohol intake, education status, bodymass
index, systolic blood pressure, diabetes mellitus, cholesterol levels and cardiovascular disease.
Findings: The prevalence of VI and ocular disease were signiﬁcantly higher in participants with CKD (36.1% and
84.7%) than in those without (12.9% and 54.3%, both p b 0.001). In multivariable models, CKD was signiﬁcantly
associated with VI (odds ratio [95% conﬁdence interval] = 1.34 [1.14–1.58]), any ocular disease (1.28 [1.03–
1.61]), cataract (1.24 [1.01–1.52]), any retinopathy (1.77 [1.45–2.15]), and DR (1.94 [1.47–2.54]).
Interpretation: The burden of VI and eye diseases is high among persons with CKD. Our ﬁndings suggest that it
may be useful to screen for ocular disease and VI in persons with CKD.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Retinopathy1. Introduction
Chronic kidney disease (CKD) is an emerging public health problem
associated with adverse cardiovascular and renal outcomes as well as
premature deaths (Chronic Kidney Disease Prognosis C et al., 2010).
The prevalence of CKD is expected to rise with the aging of the pop-
ulation worldwide. In the US, the prevalence of CKD in adults
30 years or older is projected to increase from 13.2% currently to
14.4% in 2020 and 16.7% in 2030 (Hoerger et al., 2015). In Singapore,
the age, sex-standardized prevalence of CKD was reported to be 12.8%
(Sabanayagam et al., 2010).
In addition to adverse cardiovascular and renal outcomes, patients
with CKD may also be at a higher risk of age-related ocular diseases
(Grunwald et al., 2010). Age-related ocular diseases including cataract,itute, The Academia, 20 College
(C. Sabanayagam).
. This is an open access article underretinopathy, glaucoma and age-related macular degeneration (AMD),
are leading causes of blindness in middle aged and elderly adults. As
the population ages, the prevalence of these diseases is also expected
to rise. Age-related ocular diseases share similar cardiovascular risk fac-
tors and pathogenic mechanisms including oxidative stress and inﬂam-
mation, two of the major pathogenic mechanisms underlying CKD.
Previous epidemiological studies conducted in the US have shown
CKD to be associated with cataract (Klein et al., 1998), diabetic retinop-
athy (DR) (Wong et al., 2004) and AMD (Klein et al., 2009;Weiner et al.,
2011). In a recent study, Grunwald et al. found nearly half of the partic-
ipants with CKD to have some form of fundus pathology (Grunwald
et al., 2010). Hu et al. observed a rise in intraocular pressure and de-
crease in ocular perfusion pressure in patients on hemodialysis, both
being risk factors for glaucoma development and progression (Hu
et al., 2013). Intuitively, the burden of visual impairment (VI) should
be higher in personswith CKD but the prevalence of VI and other ocular
diseases in persons with CKD are unknown, as previous studies did not
conduct a complete ophthalmological examination. Besides worseningthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
194 C.W. Wong et al. / EBioMedicine 5 (2016) 193–197the quality of life (Varma et al., 2006), VI could also contribute to all-
cause mortality in persons with CKD, through direct and indirect path-
ways (Karpa et al., 2009).
In this context, we examined the prevalence and association of CKD
with major age-related ocular diseases assessed using a comprehensive
eye examination in a population-based sample of Asian adults in
Singapore. We hypothesize that persons with CKD would have higher
prevalence of ocular diseases and VI than those without CKD.
2. Methods
2.1. Study Population and Design
The data for this study were derived from the Singapore Epidemiol-
ogy of EyeDiseases (SEED, n=10,033) Study, comprising of three inde-
pendent cross-sectional studies encompassing the three major ethnic
groups (Chinese, Malays and Indians) in Singapore: the Singapore
Malay Eye Study (SiMES, 2004–2006, n = 3280, response rate =
78.7%), the Singapore Indian Eye Study (SINDI, 2007–2009, n = 3400,
response rate = 75.6%) and the Singapore Chinese Eye Study (SCES,
2009–2011, n= 3353, response rate= 72.8%). All three studies follow-
ed similar protocols and were conducted in the same study clinic
(Singapore Eye Research Institute). The detailed methodologies of
these studies have been published elsewhere (Foong et al., 2007). In
brief, an age-stratiﬁed random sampling was used to select ethnic
Malays, Chinese and Indians 40 to 80 years of age, who were living in
Singapore during each stipulated study period. Each studywas conduct-
ed in accordance with the Declaration of Helsinki, with written in-
formed consent obtained from all subjects before participation. Ethics
approval was obtained from the SingHealth Institutional Review
Board. Of the 10,033 study participants, after excluding thosewithmiss-
ing information on serumcreatinine (n=434) and other variables (sys-
tolic blood pressure, diabetes, cardiovascular disease, total cholesterol,
corrected high density lipoprotein, body mass index, smoking status
and alcohol intake (n= 165), 9434 were included in the current analy-
sis. In addition, we excluded those with missing values on each of the
outcomes separately (AMD: 208 excluded, 9226 included; uncorrected
refractive error: 13 excluded, 9421 included; glaucoma: 0 excluded,
9424 included; any retinopathy: 205 excluded, 9229 included; DR:
7251 excluded, 2183 included; cataract: 1581 excluded, 7853 included;
VI: 38 excluded, 9396 excluded).
2.2. Study Procedures
Standardized systemic and ocular examinations, interviewer-
administered questionnaires, and standard blood investigations were
conducted for all participants. Standardized slit-lamp examinations
(Haag-Streit model BQ-900; Haag-Streit, Bern, Switzerland) were per-
formed by trained study ophthalmologists after pupil dilatation and
the fundus was examined with a 78D lens. A detailed interviewer-
administered questionnaire was used to collect relevant demographic
data and medical history from all participants. Alcohol drinkers were
deﬁned by the consumption of alcohol at least once a week. Cigarette
smoking was categorized into current, former and never smoker.
Blood pressure was measured with a digital automatic blood pressure
monitor (Dinamap model Pro Series DP110X-RW, 100V2; GE Medical
Systems Information Technologies, Inc., Milwaukee, WI, USA) after the
participants were seated for at least 5 min. The average of the 2 systolic
and diastolic blood pressuremeasurementswas used as the systolic and
diastolic blood pressure value. Venous blood samples were collected for
biochemistry tests, including serum lipids (total cholesterol, high-
density lipoprotein cholesterol, and low-density lipoprotein cholesterol),
glycosylated hemoglobin A1c (HbA1c), creatinine, and random glucose.
Diabetes mellitus was deﬁned as random glucose of 11.1 mmol/L
(Alberti and Zimmet, 1998) or more, use of diabetic medication, or aphysician diagnosis diabetes mellitus. Cardiovascular disease (CVD)
was deﬁned as self-reported myocardial infarction, angina or stroke.2.3. Assessment of CKD
CKD was deﬁned as an estimated glomerular ﬁltration rate (eGFR)
b60 mL/min/1.73 m2, using the US National Kidney Foundation Kidney
Disease Outcome Quality Initiative (KDOQI) Working Group deﬁnition
(National Kidney F, 2002). eGFR was estimated from the serum creati-
nine concentration (eGFR) (Levey et al., 2009) using the CKD Epidemi-
ology Collaboration (CKD-EPI) equation. Severity of CKD was deﬁned
by eGFR categories: ≥60 (stage 1 and 2), 30–59 (stage 3), 29–15
(stage 4) and b15 (stage 5)ml/min/1.73 m2 (National Kidney F, 2002).
Creatinine concentrations were measured by the Jaffe method on the
Beckman DXC800 analyzer. The creatinine assay was calibrated to the
isotope Dilution Mass Spectroscopy (IDMS) method using the National
Institute of Standards and Technology (NIST) Reference material.2.4. Assessment of VI
Presenting visual acuity wasmonocularlymeasured by using a loga-
rithm of the minimum angle of resolution (logmar) number chart
(Lighthouse International, New York, USA) at a distance of 4 m.
Autorefraction, was performed with an autorefractor machine (Canon
RK-5 Auto Ref-Keratometer, Canon Inc. Ltd., Japan). Final refraction
was determined by subjective refraction by trained and certiﬁed study
optometrists. Best-corrected visual acuity after subjective refraction
was monocularly assessed and recorded in logMAR scores. VI was
deﬁned as best-corrected visual acuity worse than 20/40 in the better
eye, based on the US deﬁnition (Congdon et al., 2004). Under-
corrected refractive error was deﬁned as an improvement of at least
0.2 logMAR (2 lines equivalent) in the best-corrected visual acuity
compared with the presenting visual acuity in the better eye.2.5. Cataract
A digital slit-lamp camera (Topcon model DC-1; Topcon, Japan with
FD-21 ﬂash attachment) and a Scheimpﬂug retroillumination camera
(Nidek EAS-1000, Nidek, Japan) were used to photograph the lens
through the dilated pupil. Cataract was deﬁned as the presence of nucle-
ar, cortical, or posterior subcapsular cataract using theWisconsin cataract
grading system (Klein et al., 1990).2.6. DR and any retinopathy
Fundus photography was performed using a digital non-mydriatic
retinal camera (Canon CRDGi with a 20Diopter SLR backing, Canon,
Japan) using Early Treatment for Diabetic Retinopathy Study (ETDRS)
standard ﬁeld 1 (centered on the optic disk) and ETDRS standard ﬁeld
2 (centered on the fovea). DR was considered present if characteristic
lesions as deﬁned by the Early Treatment Diabetic Retinopathy Study
were found on retinal photographs (Wong et al., 2006). DR was eval-
uated following a standard protocol based on retinal photographs
which were graded according to a modiﬁed scale from the Airlie
House classiﬁcation system by trained graders (Early Treatment
Diabetic Retinopathy Study Research Group, 1991).2.7. Age-related macular degeneration (AMD)
The presence of AMD signs was graded based on fundus photo-
graphs according to the Wisconsin Age-Related Maculopathy Grading
System (Kawasaki et al., 2008). The presence of AMD was deﬁned as
the presence of either early or late AMD.
Table 1
Characteristics of participants by CKD status.
CKD absent
(n = 8255)
CKD present
(n = 1179)
p Value*
Age (years) 57.3 (9.8) 68.3 (8.6) b0.001
Women, % 4215 (51.1) 532 (45.1) b0.001
Current smokers, % 1372 (16.6) 144 (12.2) b0.001
Alcohol drinkers, % 773 (9.4) 35 (3.0) b0.001
Primary/below educated, % 4702 (57.0) 958 (81.3) b0.001
Cardiovascular disease, % 719 (8.7) 276 (23.4) b0.001
Hypertension, % 4710 (57.2) 1044 (88.8) b0.001
Systolic blood pressure (mm Hg) 138 (21) 152 (24) b0.001
Diastolic blood pressure (mm Hg) 78 (10) 78 (11) 0.51
BMI (kg/m2) 25.31 (4.64) 26.15 (4.83) b0.001
Hyperlipidemia, % 3494 (42.5) 717 (61.2) b0.001
LDL-cholesterol (mmol/L) 3.40 (0.94) 3.22 (1.08) b0.001
HDL-cholesterol (mmol/L) 1.24 (0.37) 1.23 (0.35) 0.28
Triglycerides (mmol/L) 1.72 (1.06) 1.98 (1.38) b0.001
Diabetes mellitus, % 1749 (21.2) 502 (42.6) b0.001
Blood glucose, mmol/L 6.67 (3.26) 7.71 (4.16) b0.001
HbA1c, (%) 6.3 (1.3) 6.7 (1.5) b0.001
Anti-hypertensive medication use, % 2483 (30.2) 735 (62.9) b0.001
Lipid lowering medication use, % 1800 (21.9) 491 (42) b0.001
Diabetic medication use, % 1295 (15.8) 388 (33.2) b0.001
eGFR (mL/min/1.73m2) 89 (15) 46 (12) b0.001
Abbreviations: BMI, body mass index; LDL, low density lipoprotein; HDL, high density
lipoprotein; HbA1c, glycosylated hemoglobin; eGFR, estimated glomerular ﬁltration
rate; data presented are number of observations and proportions or mean and standard
deviation as appropriate for the variable.
Fig. 1. Prevalence of VI by eGFR categories.
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Intraocular pressure was measured with Goldmann applanation
tonometry. After pupil dilation, the optic disk was evaluated using
a +78-diopter (D) lens at ×16 magniﬁcation, with a measuring grati-
cule. Vertical cup–disk ratio exceeding 0.6 or vertical cup–disk ratio
asymmetry exceeding 0.2 A 24-2 SITA static, threshold-related visual
ﬁeld examination was performed with near refractive correction prior
to dilation using the Humphrey Visual Field Analyzer II (model 750,
Carl Zeiss, Switzerland). Test reliability was determined by the
instrument's algorithm (ﬁxation losses b20%, false positives b33%, or
false negatives b33%). Visual ﬁelds test was repeated once if deemed
unreliable. Glaucomatous visual ﬁeld loss was deﬁned as glaucoma
hemiﬁeld test graded “outside normal limits” and a cluster of three con-
tiguous points at the 5% level on the pattern deviation plot. Glaucoma
was deﬁned as the presence of both glaucomatous visual ﬁeld loss and
optic disk changes in one or both eyes (Foster et al., 2002).
2.9. Any ocular disease
Any ocular disease was deﬁned as the presence of any of the major
ocular disease including cataract, retinopathy, DR (among thosewith di-
abetes), glaucoma and AMD.
2.10. Statistical Analysis
Statistical analysis was performed with SPSS version 20.0 (Texas,
USA). A p value of b0.05was considered statistically signiﬁcant. We ex-
amined the characteristics of the participants with and without CKD
using the Chi square test for categorical variables and the independent
t test for continuous variables. The associations of CKDwith VI and ocu-
lar diseases were examined using logistic regression models: ﬁrst
adjusted for age and gender, followed by additional adjustment for po-
tential confounding factors: ethnicity, smoking, alcohol intake, educa-
tion status, body mass index, systolic blood pressure, diabetes mellitus
(duration of diabetes and HbA1c, for the analysis of DR), cholesterol
levels and CVD. In separate multivariable models, we also examined
the severity of CKDwith VI. We performed test for p-trend bymodeling
CKD stages as an ordinal variable in the corresponding multivariable
model. Finally, we repeated the multivariable analysis testing the asso-
ciation of CKD with VI stratiﬁed by diabetic status. We tested for inter-
action by diabetes in the association between CKD and VI by including
cross-product interaction terms in the multivariable logistic regression
models.
3. Results
Of the 9434 included participants, 1179 (12.5%) had CKD. The mean
eGFR in participants with and without CKD were 46 ± 12 mL/min/
1.73 m2 and 89 ± 15 mL/min/1.73 m2 respectively. Among the 1179
participants with CKD, 1051 (89.1%) had stage 3 CKD, 85 (7.2%) had
stage 4 CKD and 43 (3.7%) had stage 5 CKD. 42.6% of those with CKD
had diabetes mellitus.
Table 1 shows the baseline characteristics of participants stratiﬁed
by CKD status. Those with CKD were older, more likely to be men, pri-
mary or below educated, less likely to be current smokers, alcohol
drinkers, had higher prevalence of diabetes, hypertension, hyperlipid-
emia and CVD and had higher levels of systolic BP, BMI, triglycerides,
glucose and HbA1c levels and lower levels of LDL cholesterol levels
(all p b 0.001). Participants with CKD were also more likely to be on
anti-hypertensive, diabetic and lipid lowering medications (all
p b 0.001).
The prevalence of VI was 15.8% (n= 1481) in the study population.
The prevalence of VI was nearly three times higher in personswith CKD
than those without (36.1% vs 12.9%, p b 0.001). Fig. 1 shows the preva-
lence of VI by CKD severity. The prevalence of VI increased withdecreasing categories of eGFR (p-trend b 0.001). The prevalence of
other major ocular diseases is shown in Table 2. The prevalence of all
major ocular diseases including cataract, any retinopathy, AMD, glauco-
ma, under-corrected refractive error and any ocular diseasewere signif-
icantly higher in persons with CKD than those without. Among those
with diabetes, the prevalence of DR was also higher in those with CKD
than those without (46.0% vs 31.6%).
Table 3 shows the associations of CKD with VI and ocular diseases.
CKD was signiﬁcantly associated with VI, any ocular disease, cataract,
any retinopathy, andDR. The odds of VI increasedwith increasing sever-
ity of CKD. In models additionally adjusting for anti-hypertensive med-
ication use, the associations of CKD with VI, any ocular disease, any
retinopathy and DR remained signiﬁcant, while the association with
cataract lost signiﬁcance (Supplementary Table). In analysis stratiﬁed
by eGFR categories, compared to those with eGFR ≥ 60, the odds of VI
were 1.24 (1.05–1.48) for eGFR = 30–60, 1.71 (1.05–2.79) for
eGFR = 15–30 and 4.99 (2.46–10.13) for eGFR b 15 (data not shown).
When stratiﬁed by diabetes status (Table 4), CKD was found to be
signiﬁcantly associated with VI, and any ocular disease in persons
with diabetes. CKD was also signiﬁcantly associated with any retinopa-
thy in persons with and without diabetes. Consistent with the main
analysis, the odds of VI increased with the decreasing categories of
eGFR among those with diabetes (eGFR = 30–60: OR 1.61 95% CI
1.21–2.15; eGFR = 15–30: OR 2.24 95% CI 1.23–4.09; eGFR b 15: OR
8.43 95% CI 2.67–26.67). However, no signiﬁcant interaction was
Table 2
Prevalence of ocular disease in persons with or without CKD.
Ocular conditions CKD absent
(n = 8255)
CKD present
(n = 1179)
p Value
Visual impairment (VI) 1062 (12.9) 419 (36.1) b0.001
Any ocular disease 3706 (54.3) 731 (84.7) b0.001
Any retinopathy 848 (10.4) 265 (23.9) b0.001
*DR 540 (31.6) 218 (46.0) b0.001
AMD 500 (6.2) 121 (10.9) b0.001
Glaucoma 268 (3.2) 68 (5.8) b0.001
Cataract 2418 (34.9) 693 (74.6) b0.001
Under-corrected refractive error 1779 (21.6) 293 (25.0) 0.005
Abbreviations: CKD, chronic kidney disease; VI, visual impairment; OR, odds ratio; CI,
conﬁdence interval; DR, diabetic retinopathy; AMD, Age related macular degeneration.
Table 4
Association of CKD with VI and major ocular diseases stratiﬁed by diabetes status.
Condition Diabetes present Diabetes absent
Prevalence,
%
bMultivariable
OR (95% CI)
Prevalence,
%
aMultivariable
OR (95% CI)
VI 23.4 1.80 (1.37–2.36) 13.4 1.11 (0.89–1.38)
Any ocular
disease
91.5 1.98 (1.29–3.06) 80.0 1.07 (0.81–1.39
Any retinopathy 34.7 1.94 (1.47–2.55) 5.1 1.45 (1.01–2.07)
AMD 7.9 0.98 (0.64–1.51) 6.4 0.89 (0.66–1.20)
Glaucoma 4.6 1.11 (0.66–1.88) 3.2 0.67 (0.45–1.00)
Cataract 55.0 1.27 (0.90–1.80) 34.9 1.13 (0.87–1.48)
Under-corrected
refractive error
22.6 1.01 (0.76–1.34) 21.8 0.96 (0.78–1.17)
Abbreviations: CKD, chronic kidney disease; VI, visual impairment; OR, odds ratio; CI,
conﬁdence interval; AMD, Age related macular degeneration.
a Multivariable model adjusted for age, gender, ethnicity, education status, current
smoking, alcohol consumption, diabetes status, systolic blood pressure, body mass index,
triglyceride levels, low density lipoprotein cholesterol, and cardiovascular disease.
b Multivariable model additionally adjusted for adjusted for diabetes duration, and
HbA1c.
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tion = 0.153). In a supplementary analysis stratiﬁed by ethnicity,
although the association of CKD with VI was stronger in Indians (OR
1.81 95% CI 1.33–2.48), compared to Chinese (OR 1.01 95% CI 0.78–
1.56) and Malays (OR 1.15, 95% CI 0.90–1.46), there was no signiﬁcant
interaction by race–ethnicity (p-interaction = 0.62, data not shown).
4. Discussion
In a population-based sample ofmulti-ethnic Asian adults, we found
the prevalence of VI and major ocular diseases to be signiﬁcantly in-
creased in persons with CKD compared to those without. CKD was sig-
niﬁcantly associatedwith VI, cataract, and any retinopathy independent
of potential confounding factors. When stratiﬁed by diabetes status,
CKD showed signiﬁcant associationswith VI, DR, and any ocular disease
among persons with diabetes and with any retinopathy among those
without diabetes. The odds of VI were higher with increasing severity
of CKD, particularly in persons with diabetes.
Several large epidemiological studies have reported the prevalence
of ocular diseases in persons with CKD (Grunwald et al., 2010; Klein
et al., 2009; Weiner et al., 2011). Grunwald et al. investigated the prev-
alence of fundus pathology and glaucoma in a population based cross
sectional study of 1936 adults who participated in the Chronic Renal In-
sufﬁciency Cohort (CRIC) study. He found that 45% of persons with CKD
had ocular pathology requiring follow up examination by an ophthal-
mologist. Diabetic, hypertensive or other retinopathy was present in
25.3%, 8.9% had signs of glaucoma and 7.6% had signs of AMD. Stage 4
and 5 CKDwere associatedwith increased odds of any fundus pathology
(OR2.1295% CI 1.62–2.78) and of any retinopathy (OR 2.99 95% CI 2.05–
4.06), compared to personswith eGFR ≥ 50mL/min/1.73m2 (Grunwald
et al., 2010). In the Third National Health and Nutrition Examination
Survey (NHANES III), Weiner et al. conducted a cross sectional nestedTable 3
Associations of CKD with VI and major ocular diseases.
Age, sex adjusted
OR (95% CI)
p Value aMultivariable
adjusted OR (95% CI)
p Value
VI 1.45 (1.24–1.68) b0.001 1.34 (1.14–1.58) 0.001
Any ocular disease 1.54 (1.24–1.91) b0.001 1.28 (1.03–1.61) 0.03
Any retinopathy 2.45 (2.06–2.90) b0.001 1.77 (1.45–2.15) b0.001
bDR 1.99 (1.60–2.48) b0.001 1.94 (1.47–2.54) b0.001
AMD 0.85 (0.68–1.07) 0.16 0.93 (0.73–1.17) 0.52
Glaucoma 0.94 (0.70–1.25) 0.66 0.81 (0.60–1.10) 0.18
Cataract 1.46 (1.20–1.78) b0.001 1.24 (1.01–1.52) 0.041
Under-corrected
refractive error
0.98 (0.84–1.14) 0.82 0.98 (0.84–1.15) 0.82
Abbreviations: CKD, chronic kidney disease; VI, visual impairment; DR, diabetic retinopa-
thy; AMD, Age related macular degeneration.
a Multivariable model adjusted for age, gender, ethnicity, education status, current
smoking, alcohol consumption, diabetes status, systolic blood pressure, body mass index,
triglyceride levels, low density lipoprotein cholesterol, and cardiovascular disease.
b Multivariable model additionally adjusted for diabetes duration, and HbA1c.case control study comparingmarkers of kidney disease in 7667 persons
with and without AMD. He observed an independent association of
lower eGFR with late AMD (OR 3.05 95% CI 1.51–6.13) (Weiner et al.,
2011). In the Beaver Dam Eye Study, Klein et al. found an association
of CKD with the 15-year incidence of early AMD (OR 1.36 95% CI 1.00–
1.86) but not with exudative AMD or geographic atrophy (Klein et al.,
2009). Although the prevalence and risk of ocular disease has been re-
ported to behigh in personswith CKD, noneof these studies have exam-
ined the burden of VI in those with CKD.
The high burden of ocular disease in CKD can be explained, in part,
by the sharing of risk factors common to both kidney and eye diseases
such as age, smoking, hypertension, diabetes, raised serum cholesterol
and obesity. Ocular diseasesmay also be directly linked to CKD via com-
mon pathogenic pathways, including, atherosclerosis,microangiopathy,
inﬂammation and oxidative stress (Wong et al., 2014). In our study, cat-
aract and retinopathy were independently associated with CKD. Some
of the possible pathogenic mechanisms underlying CKD, cataract and
retinopathy are as follows: 1. Advanced glycation end products (AGEs)
are a group of structures that form under conditions of oxidative stress
or hyperglycemia. In the kidney, AGEs bind to receptors on podocytes
and endothelial cells, resulting in cellular apoptosis and upregulation
of proinﬂammatorymarkers (Busch et al., 2010). In the eye, AGEs target
lens proteins, causing crosslinking, yellowing of the lens and generation
of oxygen free radicals that lead to cataractogenesis (Ortwerth et al.,
2003). In DR, AGEs induce apoptosis of retinal pericytes, breakdown of
the inner blood retinal barrier and mediates increased expression of
proinﬂammatory cytokines in both retinal vessels and neuroglia (Stitt,
2010). High levels of serum AGEs, such as in patients with CKD, can in-
duce retinopathy similar to that seen in diabetic patients (Canning et al.,
2007) 2. Vitamin D deﬁciency, via dysregulation of the renin–angioten-
sin system, mediates increased oxidative stress, inﬂammation and
angiogenesis leading to CKD and DR (Payne et al., 2012). 3. Cystatin C,
a biomarker of CKD, has been shown to be associated with increased
risk of DR, possibly via a direct effect on vascular endothelial growth fac-
tor driven angiogenesis (Wong et al., 2015). The higher odds of retinop-
athy and VI in diabetic personswith CKD are likely to be related to some
of these common pathogenic mechanisms that are also present in per-
sons with diabetes. Thus, early intervention to preserve renal function
and adequate control of diabetes is key to the reduction of ocular disease
prevalence and low vision burden in personswith CKD. The importance
of timely and frequent eye screening in persons with both CKD and
diabetes cannot be over-emphasized.
Our study demonstrated that cataract and retinopathy were impor-
tant causes of VI in persons with CKD. With modern cataract surgical
techniques, cataract is an easily correctable cause of VI. In the Blue
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ract resulted in signiﬁcantly lower 15-year mortality risk (hazard ratio
0.54 95% CI 0.41–0.73), compared to persons with VI from cataract
that did not undergo surgery (Fong et al., 2013). In the Salisbury Eye
Evaluation project, a 53% drop in 6-year mortality risk was observed in
participants who had a gain of 2 or more lines in binocular visual acuity
2 years frombaseline examination, compared to thosewithout visual im-
provement (Freeman et al., 2005). VI secondary to DR can be corrected if
early sight threatening disease is detected and treated with laser photo-
coagulation. The high prevalence of ocular disease in persons with CKD
with readily correctable causes for VI suggests that eye screening should
be performed in all patients with reduced renal function, but there are
currently no recommendations for such screening.
In the present study, prevalence of current smoking and alcohol
drinking was found to be lower among those with CKD. It is plausible
that CKD patients may have changed their lifestyle and quit smoking
and alcohol after knowing their condition. Accordingly, when we ex-
plored the data by smoking status, 23.4% of those with CKD reported
being former smokers compared with 13.1% of those without CKD
being former smokers.
The strength of our study lies in the large sample size, population
based design, detailed eye examination and information on potential
confounders allowing an adequate estimate of the ocular disease bur-
den in persons with CKD. The cross-sectional nature of our study is a
limitation and a prospective study would be ideal to assess the inci-
dence and risk of these ocular diseases as well as VI. Second, estimation
of GFR from a single measure of serum creatinine could have
misclassiﬁed CKD status in some participants. Third, information on
other ﬁltration markers such as cystatin C was not available in two-
thirds of the participants (available only in Indian participants) and
hence was not evaluated. Fourth, we did not have information on the
etiology of CKD. Therefore, wewere unable to determine the association
of CKD with ocular diseases by speciﬁc cause of CKD.
In conclusion, there is a high burden ofmajor eye diseases in persons
with CKD, with nearly one in two suffering from VI. Cataract and reti-
nopathy are potentially reversible causes of VI, especially if treated
early. It may be useful to screen for ocular disease and VI in persons
with CKD, particularly if they also have diabetes. The results of our
study can inform public health initiatives for the prevention of CKD
and early eye screening in these high-risk individuals.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.01.023.
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